Li Mei-ping, Ren Li-fang, Cai Hong-guang, Yang Hui-ying, Lu Bo, Zhang Peng, Bao Lei
Department of Pathology, Shaoxing Women and Children Hospital, Shaoxing, China.
Zhonghua Bing Li Xue Za Zhi. 2013 Mar;42(3):182-5. doi: 10.3760/cma.j.issn.0529-5807.2013.03.009.
To study the expression of carbonic anhydrase (CA) IX and its significance in molecular subtyping of breast carcinomas. METHODL MaxVision immunohistochemical staining was used to examine the expression of ER, PR, HER2, CK5/6, EGFR, and CA IX in 117 cases of breast invasive ductal carcinomas.
The patients' age ranged from 25 to 71 years (mean 49.6 years). All the 117 cases were subclassified into five subtypes, with 66 (56.4%) luminal A, 6(5.1%) luminal B, 10 (8.6%) HER2 positive, 20 (17.1%) basal-like, and 15 (12.8%) unclassified tumors. The expression of CA IX in luminal A and basal-like breast cancers was 13.6% (9/66) and 8/20, respectively, with a significant difference (P < 0.05). Among the luminal A cancers, the expression of CA IX in tumors > 2 cm (7/27, 25.9%) was significantly (P < 0.05) higher than that of tumors ≤ 2 cm (2/39, 5.1%). The expression of CA IX in grade 3 invasive ductal carcinoma (18/50, 36.0%) was significantly higher than that in grade 1 (2/21, 9.5%) and 2 (7/46, 15.2%) tumors (both P = 0.006). In CA IX-negative of invasive ductal carcinoma, the expression of ER and PR was 61.1% (55/90) and 55.6% (50/90), respectively; whereas in CA IX-positive cancers, the expression of ER and PR was 37.0% (10/27) and 29.6% (8/27), respectively. The expression of hormone receptors in CA IX-negative tumors was significantly higher than that in CA IX-positive tumors (for both ER and PR, P < 0.05).
The expression of CA IX correlates not only with molecular subtypes of breast cancer, but also with the grading, hormone receptors and diameter of mammary invasive ductal carcinoma. CA IX is a relative independent marker of poor prognosis in breast cancer.
研究碳酸酐酶(CA)IX在乳腺癌分子亚型中的表达及其意义。方法:采用MaxVision免疫组化染色法检测117例乳腺浸润性导管癌中雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体2(HER2)、细胞角蛋白5/6(CK5/6)、表皮生长因子受体(EGFR)和CA IX的表达。
患者年龄范围为25至71岁(平均49.6岁)。117例病例被分为五个亚型,其中管腔A型66例(56.4%),管腔B型6例(5.1%),HER2阳性型10例(8.6%),基底样型20例(17.1%),未分类肿瘤15例(12.8%)。CA IX在管腔A型和基底样型乳腺癌中的表达分别为13.6%(9/66)和8/20,差异有统计学意义(P<0.05)。在管腔A型癌中,肿瘤>2 cm者CA IX的表达(7/27,25.9%)明显高于肿瘤≤2 cm者(2/39,5.1%)(P<0.05)。Ⅲ级浸润性导管癌中CA IX的表达(18/50,36.0%)明显高于Ⅰ级(2/21,9.5%)和Ⅱ级(7/46,15.2%)肿瘤(P均=0.006)。在浸润性导管癌CA IX阴性病例中,ER和PR的表达分别为61.1%(55/90)和55.6%(50/90);而在CA IX阳性癌中,ER和PR的表达分别为37.0%(10/27)和29.6%(8/27)。CA IX阴性肿瘤中激素受体的表达明显高于CA IX阳性肿瘤(ER和PR均P<0.05)。
CA IX的表达不仅与乳腺癌的分子亚型有关,还与乳腺浸润性导管癌的分级、激素受体及直径有关。CA IX是乳腺癌预后不良的一个相对独立的标志物。